Referências

1. Biere S.S., van Berge Henegouwen M.I., Maas K.W., Bonavina L., Rosman C., Garcia J.R., Gisbertz S.S., Klinkenbijl J.H., Hollmann M.W., de Lange E.S., Bonjer H.J., van der Peet D.L., Cuesta M.A., Minimally invasive versus open oesophagectomy for patients with oesophageal cancer:A multicentre, open-label, randomised controlled trial, Lancet, 379, 9829, pp. 1887-1892, (2012)
2. Low D.E., Kuppusamy M.K., Alderson D., Cecconello I., Chang A.C., Darling G., Davies A., D'Journo X.B., Gisbertz S.S., Griffin S.M., Hardwick R., Hoelscher A., Hofstetter W., Jobe B., Kitagawa Y., Law S., Mariette C., Maynard N., Morse C.R., Nafteux P., Pera M., Pramesh C.S., Puig S., Reynolds J.V., Schroeder W., Smithers M., Wijnhoven B.P.L., Benchmarking complications associated with esophagectomy, Ann Surg, 269, 2, pp. 291-298, (2019)
3. Takubo K., Pathology of the esophagus, pp. 194-203, (2000)
4. Hashimoto C.L., Iriya K., Baba E.R., Navarro-Rodriguez T., Zerbini M.C., Eisig J.N., Barbuti R., Chinzon D., Moraes-Filho J.P., Lugol’s dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer, Am J Gastroenterol, 100, 2, pp. 275-282, (2005)
5. Brown L.M., Devesa S.S., Epidemiologic trends in esophageal and gastric cancer in the United States, Surg Oncol Clin N Am, 11, 2, pp. 235-256, (2002)
6. Tustumi F., Takeda F.R., Kimura C.M., Sallum R.A., Ribeiro U., Cecconello I., Esophageal carcinoma: Is squamous cell carcinoma different disease compared to adenocarcinoma? A transversal study in a quaternary high volume hospital in Brazil, Arq Gastroenterol, 53, 1, pp. 44-48, (2016)
7. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, (2001)
8. Rice T.W., Ishwaran H., Ferguson M.K., Blackstone E.H., Goldstraw P., Cancer of the esophagus and esophagogastric junction: An eighth edition staging primer, J Thorac Oncol, 12, 1, pp. 36-42, (2017)
9. Mota F.C., Cecconello I., Takeda F.R., Tustumi F., Sallum R.A.A., Bernardo W.M., Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options, Int J Surg, 54, pp. 176-181, (2018)
10. Van Hagen P., Hulshof M.C., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., Cuesta M.A., Blaisse R.J., Busch O.R., ten Kate F.J., Creemers G.J., Punt C.J., Plukker J.T., Verheul H.M., Spillenaar Bilgen E.J., van Dekken H., van der Sangen M.J., Rozema T., Biermann K., Beukema J.C., Piet A.H., van Rij C.M., Reinders J.G., Tilanus H.W., van der Gaast A., Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 22, pp. 2074-2084, (2012)
11. Al-Batran S.E., Homann N., Schmalenberg H., Kopp H.G., Haag G.M., Luley K.B., Et al., Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial, J Clin Oncol, 35, 15, (2017)
12. Borggreve A.S., Kingma B.F., Domrachev S.A., Koshkin M.A., Ruurda J.P., van Hillegersberg R., Takeda F.R., Goense L., Surgical treatment of esophageal cancer in the era of multimodality management, Ann N Y Acad Sci, 1434, 1, pp. 192-209, (2018)
13. Takeda F.R., Tustumi F., Nigro B.C., Sallum R.A.A., Ribeiro Junior U., Cecconello I., Transhiatal esophagectomy is not associated with poor quality lymphadenectomy, Arq Bras Cir Dig, 32, 4, (2019)
14. Lerut T., De Leyn P., Coosemans W., Van Raemdonck D., Scheys I., LeSaffre E., Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy, Ann Surg, 216, 5, pp. 583-590, (1992)
15. Hagen J.A., Peters J.H., DeMeester T.R., Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia, J Thorac Cardiovasc Surg, 106, 5, pp. 850-858, (1993)
16. Markar S.R., Arya S., Karthikesalingam A., Hanna G.B., Technical factors that affect anastomotic integrity following esophagectomy: Systematic review and meta-analysis, Ann Surg Oncol, 20, 13, pp. 4274-4281, (2013)
17. Takeda F.R., Cecconello I., Ribeiro U., Sallum R.A.A., Comparative study of transhiatal and transthoracic thoracoscopic esophagectomy results in adenocarcinoma of the esophagogastric junction, J Clin Oncol, 36, 4, (2018)
18. Takeda F.R., Tutihashi R., Tustumi F., Et al., Supercharged cervical anastomosis for esophagectomy and gastric pull-up, J Thorac Cardiovasc Surg, 162, 3, pp. 688-697, (2020)
19. Watanabe M., Nakajima M., Nishikawa K., Kato H., Matsubara H., Thoracic endovascular aortic repair for esophageal cancer invading the thoracic aorta: A questionnaire survey study, Esophagus, 17, 1, pp. 74-80, (2020)
20. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J., Helicobacter pylori infection and the development of gastric cancer, N Engl J Med, 345, pp. 784-789, (2001)
21. Ajani J.A., D'Amico T.A., Almhanna K., Bentrem D.J., Chao J., Das P., Et al., Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw, 14, 10, pp. 1286-1312, (2016)
22. De Manzoni G., Marrelli D., Baiocchi G.L., Morgagni P., Saragoni L., Degiuli M., Et al., The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015, Gastric Cancer, 20, 1, pp. 20-30, (2017)
23. Japanese gastric cancer treatment guidelines 2018 (5th edition), Gastric Cancer, 24, pp. 1-21, (2021)
24. Ribeiro U., Safatle-Ribeiro A.V., Zilberstein B., Et al., Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection?, J Gastrointest Surg, 10, 2, pp. 170-177, (2006)
25. Zilberstein B., da Costa M.B., Jacob C.E., Bresciani C., Lopasso F.P., de Cleva R., Pinto Junior P.E., Junior U.R., Perez R.O., Gama-Rodrigues J., Complications of gastrectomy with lymphadenectomy in gastric cancer, Gastric Cancer, 7, pp. 254-259, (2004)
26. Japanese gastric cancer treatment guidelines 2014 (ver.4), Gastric Cancer, 20, 1, pp. 1-19, (2017)
27. Gotoda T., Yanagisawa A., Sasako M., Ono H., Nakanishi Y., Shimoda T., Kato Y., Incidence of lymph node metastasis from early gastric cancer: Estimation with a large number of cases from two large centers, Gastric Cancer, 3, pp. 219-225, (2000)
28. Macdonald J.S., Smalley S.R., Benedetti J., Et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 10, pp. 725-730, (2001)
29. Cunningham D., Allum W.H., Stenning S.P., Et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 1, pp. 11-20, (2006)
30. Sakuramoto S., Sasako M., Yamaguchi T., Et al., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [published correction appears in N Engl J Med. 2008;358(18):1977], N Engl J Med, 357, 18, pp. 1810-1820, (2007)
31. Bang Y.J., Kim Y.W., Yang H.K., Et al., Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial, Lancet, 379, 9813, pp. 315-321, (2012)
32. Lee J., Lim D.H., Kim S., Et al., Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial, J Clin Oncol, 30, 3, pp. 268-273, (2012)
33. Sano T., Aiko T., New Japanese classification and treatment guidelines for gastric câncer: Revision concepts and major revised points, Gastric Cancer, 14, pp. 97-100, (2011)
34. Global Cancer Observatory, (2018)
35. Ilic M., Ilic I., Epidemiology of pancreatic cancer, World J Gastroenterol, 22, pp. 9694-9705, (2016)
36. Wong M.C.S., Jiang J.Y., Liang M., Fang Y., Yeung M.S., Sung J.J.Y., Global temporal patterns of pancreatic cancer and association with socioeconomic development, Sci Rep, 7, (2017)
37. Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2017, CA Cancer J Clin, 67, pp. 7-30, (2017)
38. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial, JAMA, 304, pp. 1073-1081, (2010)
39. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial, Lancet, 389, pp. 1011-1024, (2017)
40. A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas, J Clin Oncol, 36, pp. LBA4001-LBA4001, (2018)
41. Ghosn M., Kourie H.R., El Rassy E., Et al., Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature, World J Gastrointest Oncol, 8, 10, pp. 745-750, (2016)
42. Labori K.J., Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial -1 (NorPACT-1)) -study protocol for a national multicentre randomized controlled trial, BMC Surg, 17, (2017)
43. Zhan H.X., Xu J.W., Wu D., Wu Z.Y., Wang L., Hu S.Y., Zhang G.Y., Neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of prospective studies, Cancer Med, 6, pp. 1201-1219, (2017)
44. Chua T.C., Saxena A., Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results, Surg Oncol, 20, 4, pp. e161-e168, (2011)
45. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Stewart A.K., Winchester D.P., Talamonti M.S., National failure to operate on early stage pancreatic cancer, Ann Surg, 246, 2, pp. 173-180, (2007)
46. Isaji S., Mizuno S., Windsor J.A., Et al., International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017, Pancreatology, 18, 1, pp. 2-11, (2018)
47. Christians K.K., Tsai S., Mahmoud A., Et al., Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm?, Oncologist, 19, 3, pp. 266-274, (2014)
48. Christians K.K., Heimler J.W., George B., Et al., Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy, Surgery, 159, 3, pp. 893-900, (2016)
49. Evans D.B., Crane C.H., Charnsangavej C., Et al., The added value of multidisciplinary care for patients with pancreatic cancer, Ann Surg Oncol, 15, 8, pp. 2078-2080, (2008)
50. Cusack J.C., Fuhrman G.M., Lee J.E., Evans D.B., Managing unsuspected tumor invasion of the superior mesenteric portal venous confluence during pancreaticoduodenectomy, Am J Surg, 168, pp. 352-354, (1994)
51. Harrison L.E., Klimstra D.S., Brennan M.F., Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?, Ann Surg, 224, pp. 342-347, (1996)
52. Shimada K., Sano T., Sakamoto Y., Kosuge T., Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma, Ann Surg Oncol, 13, pp. 1569-1578, (2006)
53. Shimoda M., Mori S., Kita J., Sawada T., Kubota K., Results of pancreaticoduodenectomy with portal or superior mesenteric vein resection for locally advanced pancreatic head cancer, Hepato-Gastroenterology, 60, 128, pp. 2094-2098, (2013)
54. Ramacciato G., Mercantini P., Petrucciani N., Et al., Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma?, Ann Surg Oncol, 16, 4, pp. 817-825, (2009)
55. Gong Y., Zhang L., He T., Et al., Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: A multicenter, retrospective analysis, PLoS One, 8, 8, (2013)
56. Yu X.Z., Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: A meta-analysis, Eur J Surg Oncol, 40, pp. 371-378, (2014)
57. Bockhorn M., Uzunoglu F.G., Adham M., Et al., Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS), Surgery, 155, 6, pp. 977-988, (2014)
58. Mollberg N., Rahbari N.N., Koch M., Et al., Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis, Ann Surg, 254, 6, pp. 882-893, (2011)
59. Younan G., Tsai S., Evans D.B., Christians K.K., Techniques of vascular resection and reconstruction in pancreatic cancer, Surg Clin North Am, 96, 6, pp. 1351-1370, (2016)
60. Kurihara C., Yoshimi F., Sasaki K., Et al., Impact of portal vein invasion and resection length in pancreatoduodenectomy on the survival rate of pancreatic head cancer, Hepato-Gastroenterology, 60, 127, pp. 1759-1765, (2013)
61. Buchs N.C., Chilcott M., Poletti P.A., Buhler L.H., Morel P., Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management, World J Gastroenterol, 16, 7, pp. 818-831, (2010)
62. Banz V.M., Croagh D., Coldham C., Et al., Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas, Eur J Surg Oncol, 38, 1, pp. 72-79, (2012)
63. Tempero M.A., Malafa M.P., Al-Hawary M., Et al., Pancreatic adenocarcinoma, version 2. 2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Cancer Netw, 15, 8, pp. 1028-1061, (2017)
64. Riediger H., Makowiec F., Fischer E., Adam U., Hopt U.T., Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection, J Gastrointest Surg, 10, pp. 1106-1115, (2006)
65. Carrere N., Sauvanet A., Goere D., Kianmanesh R., Vullierme M.P., Couvelard A., Ruszniewski P., Belghiti J., Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of the pancreatic head, World J Surg, 30, pp. 1526-1535, (2006)
66. van Geenen R.C., ten Kate F.J., de Wit L.T., van Gulik T.M., Obertop H., Gouma D.J., Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy, Surgery, 129, pp. 158-163, (2001)
67. Howard T.J., Villanustre N., Moore S.A., DeWitt J., LeBlanc J., Maglinte D., McHenry L., Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head, J Gastrointest Surg, 7, pp. 1089-1095, (2003)
68. Gong Y., Zhang L., He T., Ding J., Zhang H., Chen G., Et al., Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer:A multicenter, retrospective analysis, PLoS One, 8, (2013)
69. Castleberry A.W., White R.R., De La Fuente S.G., Et al., The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database, Ann Surg Oncol, 19, 13, pp. 4068-4077, (2012)
70. Aramaki M., Matsumoto T., Etoh T., Ishio T., Himeno Y., Sasaki A., Yada K., Kawano K., Kitano S., Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma, Hepato-Gastroenterology, 50, pp. 263-266, (2003)
71. Bachellier P., Nakano H., Oussoultzoglou P.D., Weber J.C., Boudjema K., Wolf P.D., Jaeck D., Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?, Am J Surg, 182, pp. 120-129, (2001)
72. Leach S.D., Lee J.E., Charnsangavej C., Cleary K.R., Lowy A.M., Fenoglio C.J., Pisters P.W., Evans D.B., Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head, Br J Surg, 85, pp. 611-617, (1998)
73. Shibata C., Kobari M., Tsuchiya T., Arai K., Anzai R., Takahashi M., Uzuki M., Sawai T., Yamazaki T., Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas, World J Surg, 25, pp. 1002-1005, (2001)
74. Li B., Chen F.Z., Ge X.H., Cai M.Z., Jiang J.S., Li J.P., Lu S.H., Pancreatoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic head, Hepatobiliary Pancreat Dis Int, 3, pp. 612-615, (2004)
75. Clavien P.A., Rudiger H.A., A simple technique of portal vein resection and reconstruction during pancreaticoduodenectomy, J Am Coll Surg, 189, 6, pp. 629-634, (1999)
76. Machado M.C., Penteado S., Cunha J.E., Et al., Pancreatic head tumors with portal vein involvement:An alternative surgical approach, Hepato-Gastroenterology, 48, 41, pp. 1486-1487, (2001)
77. Machado M.C., Figueira E.R., Machado M.A., Et al., Portal vein resection: A modified technique for reconstruction after pancreaticoduodenectomy, J Surg Oncol, 88, 1, pp. 52-54, (2004)
78. Del Chiaro M., Rangelova E., Halimi A., Et al., Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer, HPB, 21, pp. 219-225, (2019)
79. Boggi U., Del Chiaro M., Croce C., Et al., Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer, Surgery, 146, pp. 869-881, (2009)
80. Tee M.C., Krajewski A.C., Groeschl R.T., Et al., Indications and perioperative outcomes for pancreatectomy with arterial resection, J Am Coll Surg, 227, 2, pp. 255-269, (2018)
81. Hackert T., Strobel O., Michalski C.W., Et al., The TRIANGLE operation -radical surgery after neoadjuvant treatment for advanced pancreatic cancer: A single arm observational study, HPB, 19, 11, pp. 1001-1007, (2017)
82. Machado M.C., Penteado S., Montagnini A.L., Machado M.A., An alternative technique in the treatment of celiac axis stenosis diagnosed during pancreaticoduodenectomy, HPB Surg, 10, 6, pp. 371-373, (1998)
83. Klompmaker S., De Rooij T., Korteweg J.J., Et al., Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer, BJS, 103, 8, pp. 941-949, (2016)
84. Klompmaker S., van Hilst J., Gerritsen S.L., Et al., Outcomes after distal pancreatectomy with celiac axis resection for pancreatic cancer: A Pan-European retrospective cohort study, Ann Surg Oncol, 25, 5, pp. 1440-1447, (2018)
85. Klompmaker S., Peters N.A., van Hilst J., Et al., Outcomes and risk score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An international multicenter analysis, Ann Surg Oncol, 26, 3, pp. 772-781, (2019)
86. Kondo S., Katoh H., Shimizu T., Et al., Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer, Hepatogastroenterology, 47, 35, pp. 1447-1449, (2000)
87. Nakamura T., Hirano S., Noji T., Et al., Distal pancreatectomy with en bloc celiac axis resection (modified Appleby procedure) for locally advanced pancreatic body cancer: A single-center review of 80 consecutive patients, Ann Surg Oncol, 23, pp. 969-975, (2016)
88. Cesaretti M., Abdel-Rehim M., Barbier L., Dokmak S., Hammel P., Sauvanet A., Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma:A major procedure for selected patients, J Visc Surg, 153, 3, pp. 173-181, (2016)
89. Kimura A., Yamamoto J., Aosasa S., Et al., Importance of maintaining left gastric arterial flow at Appleby operation preserving whole stomach for central pancreatic cancer, Hepato-Gastroenterology, 59, 120, pp. 2650-2652, (2012)
90. Okada K., Kawai M., Tani M., Et al., Preservation of the left gastric artery on the basis of anatomical features in patients undergoing distal pancreatectomy with celiac axis en-bloc resection (DP-CAR), World J Surg, 38, 11, pp. 2980-2985, (2014)
91. Sato T., Saiura A., Inoue Y., Takahashi Y., Arita J., Takemura N., Distal pancreatectomy with en bloc resection of the celiac axis with preservation or reconstruction of the left gastric artery in patients with pancreatic body cancer, World J Surg, 40, 9, pp. 2245-2253, (2016)
92. Machado M.A., Surjan R.C., Nishinari K., Makdissi F.F., Machado M.C., Iliac-hepatic arterial bypass for compromised collateral flow during modified Appleby operation for advanced pancreatic cancer, Eur J Surg Oncol, 35, 10, pp. 1124-1127, (2009)
93. Mittal A., de Reuver P.R., Shanbhag S., Et al., Distal pancreatectomy, splenectomy, and celiac axis resection (DPS-CAR): Common hepatic arterial stump pressure should determine the need for arterial reconstruction, Surgery, 157, 4, pp. 811-817, (2015)
94. Peters N.A., Javed A.A., Cameron J.L., Et al., Modified Appleby procedure for pancreatic adenocarcinoma:Does improved neoadjuvant therapy warrant such an aggressive approach?, Ann Surg Oncol, 23, 11, pp. 3757-3764, (2016)
95. Sugiura T., Okamura Y., Ito T., Yamamoto Y., Uesaka K., Surgical indications of distal pancreatectomy with celiac axis resection for pancreatic body/tail cancer, World J Surg, 41, 1, pp. 258-266, (2017)
96. Bismuth H., Nakache R., Diamond T., Management strategies in resection for hilar cholangiocarcinoma, Ann Surg, 215, 1, pp. 31-38, (1992)
97. de Jong M.C., Marques H., Clary B.M., Et al., The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases, Cancer, 118, 19, pp. 4737-4747, (2012)
98. Laurent A., Tayar C., Cherqui D., Cholangiocarcinoma: Preoperative biliary drainage (Con), HPB, 10, 2, pp. 126-129, (2008)
99. Neuhaus P., Jonas S., Bechstein W.O., Et al., Extended resections for hilar cholangiocarcinoma, Ann Surg, 230, 6, pp. 808-819, (1999)
100. Neuhaus P., Thelen A., Jonas S., Et al., Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma, Ann Surg Oncol, 19, 5, pp. 1602-1608, (2012)
101. Hemming A.W., Mekeel K., Khanna A., Baquerizo A., Kim R.D., Portal vein resection in management of hilar cholangiocarcinoma, J Am Coll Surg, 212, 4, pp. 604-616, (2011)
102. Machado M.A., Makdissi F.F., Surjan R.C., Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma: No-touch technique, Ann Surg Oncol, 19, 4, pp. 1324-1325, (2012)
103. Abbas S., Sandroussi C., Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma, HPB, 15, 7, pp. 492-503, (2013)
104. Chen W., Et al., Combined portal vein resection in the treatment of hilar cholangiocarcinoma:A systematic review and meta-analysis, Eur J Surg Oncol, 40, 5, pp. 489-495, (2014)
105. Sakamoto Y., Sano T., Shimada K., Et al., Clinical significance of reconstruction of the right hepatic artery for biliary malignancy, Langenbeck’s Arch Surg, 391, 3, pp. 203-208, (2006)
106. Gerhards M.F., van Gulik T.M., de Wit L.T., Obertop H., Gouma D.J., Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience, Surgery, 127, 4, pp. 395-404, (2000)
107. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 6, pp. 394-424, (2018)
108. CANCER
109. INCA
110. São Paulo colorectal cancer mortality
111. DiSario J.A., Burt R.W., Kendrick M.L., McWhorter W.P., Colorectal cancers of rare histologic types compared with adenocarcinomas, Dis Colon Rectum, 37, 12, pp. 1277-1280, (1994)
112. Morson B.C., Evolution of cancer of the colon and rectum, Cancer, 34, 3, pp. 845-849, (1974)
113. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Et al., Genetic alterations during colorectal-tumor development, N Engl J Med, 319, 9, pp. 525-532, (1988)
114. Nair R.M., Siegel E.M., Chen D.T., Fulp W.J., Yeatman T.J., Malafa M.P., Et al., Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum, J Gastrointest Surg, 12, pp. 1797-1805, (2008)
115. Siegel R.L., Miller K.D., Fedewa S.A., Ahnen D.J., Meester R.G.S., Barzi A., Et al., Colorectal cancer statistics, 2017, CA Cancer J Clin, 67, 3, pp. 177-193, (2017)
116. Dekker E., Tanis P.J., Vleugels J.L.A., Kasi P.M., Wallace M.B., Colorectal cancer, Lancet, 394, 10207, pp. 1467-1480, (2019)
117. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 4, 12, pp. 913-933, (2019)
118. Weiser M.R., AJCC 8th edition: Colorectal cancer, Annals of surgical oncology, 25, pp. 1454-1455, (2018)
119. Mahar A.L., Compton C., Halabi S., Hess K.R., Weiser M.R., Groome P.A., Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes, J Surg Oncol, 116, 8, pp. 969-982, (2017)
120. Campos-da-Paz M., Dorea J.G., Galdino A.S., Lacava Z.G.M., de Fatima Menezes Almeida Santos M., Carcinoembryonic Antigen (CEA) and hepatic metastasis in colorectal cancer:Update on biomarker for clinical and biotechnological approaches, Recent Pat Biotechnol, 12, 4, pp. 269-279, (2018)
121. Liebig-Horl G., Puchner C., Gerken M., Klinkhammer-Schalke M., Furst A., [Treatment strategy for early stage rectal cancer (T1 carcinoma)], Chirurg, 89, 5, pp. 358-364, (2018)
122. Daniels I.R., Strassburg J., Moran B.J., The need for future surgical low rectal cancer studies, Colorectal Dis, 8, pp. 25-29, (2006)
123. Battersby N.J., How P., Moran B., Stelzner S., West N.P., Branagan G., Et al., Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: The MERCURY II Study, Ann Surg, 263, 4, pp. 751-760, (2016)
124. Benson A.B., Venook A.P., Al-Hawary M.M., Cederquist L., Chen Y.-J., Ciombor K.K., Et al., Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw, 16, 7, pp. 874-901, (2018)
125. Wilkinson N., Management of rectal cancer, Surg Clin North Am, 100, 3, pp. 615-628, (2020)
126. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Rodel C., Cervantes A., Et al., Rectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, pp. iv22-iv40, (2017)
127. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study, BMJ, 333, 7572, (2006)
128. Maeda K., Koide Y., Katsuno H., When is local excision appropriate for “early” rectal cancer?, Surg Today, 44, 11, pp. 2000-2014, (2014)
129. You Y.N., Hardiman K.M., Bafford A., Poylin V., Francone T.D., Davis K., Et al., The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer, Dis Colon Rectum, 63, 9, pp. 1191-1222, (2020)
130. Bahadoer R.R., Dijkstra E.A., van Etten B., Marijnen C.A.M., Putter H., Kranenbarg E.M.-K., Et al., Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial, Lancet Oncol, 22, 1, pp. 29-42, (2021)
131. Feeney G., Sehgal R., Sheehan M., Hogan A., Regan M., Joyce M., Et al., Neoadjuvant radiotherapy for rectal cancer management, World J Gastroenterol, 25, 33, pp. 4850-4869, (2019)
132. Nahas S.C., Nahas C.S.R., Cama G.M., de Azambuja R.L., Horvat N., Marques C.F.S., Et al., Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer, Abdom Radiol, 44, 11, (2019)
133. Nahas C.S.R., Nahas S.C., Ribeiro-Junior U., Bustamante-Lopez L., Marques C.F.S., Pinto R.A., Et al., Prognostic factors affecting outcomes in multivisceral en bloc resection for colorectal cancer, Clinics, 72, 5, pp. 258-264, (2017)
134. Surgical and Survival Outcomes Following Pelvic Exenteration for Locally Advanced Primary Rectal Cancer: Results From an International Collaboration, Ann Surg, 269, 2, pp. 315-321, (2019)
135. Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer, BJS open, 3, 4, pp. 516-520, (2019)
136. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes, Br J Surg, 100, 8, pp. 1009-1014, (2013)
137. Jorge J.M.N., Habr-Gama A., The ASCRS Textbook of Colon and Rectal Surgery, pp. 1-32, (2007)
138. Nelson H., Petrelli N., Carlin A., Couture J., Fleshman J., Guillem J., Et al., Guidelines 2000 for colon and rectal cancer surgery, J Natl Cancer Inst, 93, 8, pp. 583-596, (2001)
139. Hohenberger W., Weber K., Matzel K., Papadopoulos T., Merkel S., Standardized surgery for colonic cancer: Complete mesocolic excision and central ligation--technical notes and outcome, Color Dis, 11, 4, pp. 354-355, (2009)
140. Alhanafy M.K., Park S.S., Park S.C., Park B., Kim M.J., Sohn D.K., Et al., Early experience with transanal total mesorectal excision compared with laparoscopic total mesorectal excision for rectal cancer: A propensity score-matched analysis, Dis Colon Rectum, 63, 11, pp. 1500-1510, (2020)
141. Wang C., Gao Z., Shen K., Shen Z., Jiang K., Liang B., Et al., Safety, quality and effect of complete mesocolic excision vs non-complete mesocolic excision in patients with colon cancer:A systemic review and meta-analysis, Color Dis, 19, 11, pp. 962-972, (2017)
142. Fingerhut A., Tzu-Liang Chen W., Boni L., Uranues S., Complete mesocolic excision for colonic cancer, Minerva Chir, 74, 2, pp. 148-159, (2019)
143. Monson J.R.T., Weiser M.R., Buie W.D., Chang G.J., Rafferty J.F., Buie W.D., Et al., Practice parameters for the management of rectal cancer (Revised), Dis Colon Rectum, 56, 5, pp. 535-550, (2013)
144. Heald R.J., Ryall R.D., Recurrence and survival after total mesorectal excision for rectal cancer, Lancet, 1, 8496, pp. 1479-1482, (1986)
145. MacFarlane J.K., Ryall R.D., Heald R.J., Mesorectal excision for rectal cancer, Lancet, 341, 8843, (1993)
146. Bleday R., Et al., UpToDate, (2019)
147. Germanos S., Bolanis I., Saedon M., Baratsis S., Control of presacral venous bleeding during rectal surgery, Am J Surg, 200, 2, pp. e33-e35, (2010)
148. Casal Nunez J.E., Vigorita V., Ruano Poblador A., Gay Fernandez A.M., Toscano Novella M.A., Caceres Alvarado N., Et al., Presacral venous bleeding during mobilization in rectal cancer, World J Gastroenterol, 23, 9, pp. 1712-1719, (2017)
149. Celentano V., Ausobsky J.R., Vowden P., Surgical management of presacral bleeding, Ann R Coll Surg Engl, 96, 4, pp. 261-265, (2014)
150. Takahashi T., Ueno M., Azekura K., Ohta H., Lateral node dissection and total mesorectal excision for rectal cancer, Dis Colon Rectum, 43, 10, pp. S59-S68, (2000)
151. Williamson J.S., Quyn A.J., Sagar P.M., Rectal cancer lateral pelvic sidewall lymph nodes: A review of controversies and management, Br J Surg, 107, 12, pp. 1562-1569, (2020)
152. Cameron M.G., Kersten C., Vistad I., Fossa S., Guren M.G., Palliative pelvic radiotherapy of symptomatic incurable rectal cancer -a systematic review, Acta Oncol, 53, 2, pp. 164-173, (2014)
153. Cedermark B., Dahlberg M., Glimelius B., Pahlman L., Rutqvist L.E., Wilking N., Improved survival with preoperative radiotherapy in resectable rectal cancer, N Engl J Med, 336, 14, pp. 980-987, (1997)
154. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., Putter H., Steup W.H., Wiggers T., Et al., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer, N Engl J Med, 345, 9, pp. 638-646, (2001)
155. Habr-Gama A., Perez R.O., Proscurshim I., Nunes Dos Santos R.M., Kiss D., Gama-Rodrigues J., Et al., Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: Does delayed surgery have an impact on outcome?, Int J Radiat Oncol Biol Phys, 71, 4, pp. 1181-1188, (2008)
156. Bujko K., Wyrwicz L., Rutkowski A., Malinowska M., Pietrzak L., Krynski J., Et al., Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: Results of a randomized phase III study, Ann Oncol, 27, 5, pp. 834-842, (2016)
157. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., Et al., Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 351, 17, pp. 1731-1740, (2004)
158. van der Valk M.J.M., Hilling D.E., Bastiaannet E., Meershoek-Klein Kranenbarg E., Beets G.L., Figueiredo N.L., Et al., Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch and Wait Database (IWWD): An international multicentre registry study, Lancet, 391, 10139, pp. 2537-2545, (2018)
159. Papaccio F., Rosello S., Huerta M., Gambardella V., Tarazona N., Fleitas T., Et al., Neoadjuvant chemotherapy in locally advanced rectal cancer, Cancers, 12, 12, (2020)